Bio-Path Holdings, Inc. issued shares and warrants to its CEO's advisory firm on January 2, 2026, as part of a restructure involving $10,000 in accrued payables, and plans to domesticate to Wyoming by March 2026. They are also restructuring their drug trial processes and enhancing their operations with new advisory support.